Flouria Health

Digital clinic providing personalized hormonal health care for women across life stages including perimenopause and fertility.

Website: https://flouria.health/

Cover Block

Open sources

Field	Value
Name	Flouria Health
Tagline	Digital clinic providing personalized hormonal health care for women across life stages including perimenopause and fertility.
Headquarters	Amsterdam, Netherlands [ABN AMRO, December 2025]
Founded	2024 [ABN AMRO, December 2025]
Stage	Seed [Flouria Health, October 2026]
Business model	Direct-to-Consumer (DTC)
Industry	Healthtech
Technology type	Software (Non-AI)
Geography	Western Europe
Growth profile	Venture Scale
Founding team	Co-Founders (3+) [Women Disrupting Tech, May 2025]
Funding label	Seed [Flouria Health, October 2026]
Total disclosed	€1.5 million [Flouria Health, October 2026]

What an Investor Needs First

PUBLIC Flouria Health is an Amsterdam-based digital clinic focused on women’s hormonal health, and it merits attention now because it has moved from launch into early proof of demand while also disclosing €1.5 million in seed funding backed by Healthy.Capital [Flouria Health, October 2026] [Femtech Insider, October 2026] [Startup.eu, October 2026]. The company was founded in 2024, according to an ABN AMRO interview with co-founder and CEO Jeanine van Munster, and publicly described its consumer proposition as launching in October 2025, which gives investors a relatively recent operating window to evaluate early uptake rather than a long, under-documented incubation period [ABN AMRO, December 2025] [Startup.eu, October 2026].

The product appears to center on online specialist care for life-stage and hormone-related needs, with the company specifically presenting a perimenopause care path that includes expert consultations and HRT prescribing; third-party coverage also describes a broader scope spanning fertility and related hormonal conditions [Flouria Health, retrieved 2026] [Femtech Insider, October 2026]. The differentiated claim, based mainly on company materials and re-reported coverage, is that Flouria is trying to package consultation, testing, tracking, and individualized treatment planning into one consumer-facing clinic rather than leaving patients to assemble care across separate providers [Flouria Health, retrieved 2026] [Startup.eu, October 2026].

The founding bench is legible, if still lightly documented in public sources: Jeanine van Munster is identified publicly as co-founder and CEO, Vlatko Stojkovski as co-founder and CTO, and Anna Christie as co-founder and CCO [LinkedIn, retrieved 2026] [The Org, retrieved 2026] [Apple Podcasts, retrieved 2026]. Publicly available profile data suggests a mix of finance, technology, and commercial leadership, which is directionally sensible for an early consumer health company, though the medical and regulatory execution burden will matter more than title coverage alone as the company scales [LinkedIn, retrieved 2026] [Flouria Health, October 2026].

On traction, the clearest public operating datapoint is that Flouria had served more than 1,000 women since the October 2025 launch of its consumer proposition, according to Femtech Insider and Startup.eu [Femtech Insider, October 2026] [Startup.eu, October 2026]. The business model is direct-to-consumer, and the next 12 to 18 months will likely hinge on whether that early patient volume can translate into repeat engagement, efficient acquisition, and disciplined expansion beyond the Netherlands without fragmenting the care experience that underpins the current pitch [Flouria Health, October 2026] [Femtech Insider, October 2026].

Partially corroborated -- Core facts on funding, launch timing, and early traction are supported by named public sources, but several product-scope and team-background details remain company-led or only partially corroborated.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed, total disclosed approximately $1,590,000

Inside the Company

Overview

PUBLIC Flouria Health is an Amsterdam-based digital women’s health clinic founded in 2024, according to the company’s website and a December 2025 ABN AMRO interview with co-founder Jeanine van Munster [Flouria Health, retrieved 2026] [ABN AMRO, December 2025]. The company presents itself as focused on hormonal health and frames its care model around online support for women across different life stages, with a consumer-facing proposition in market by October 2025 [Flouria Health, retrieved 2026] [Startup.eu, October 2026].

The public record is still early, but the chronology is clear enough to matter. Jeanine van Munster’s public profile indicates she had been serving as co-founder and CEO since September 2023, which suggests company formation work predated the stated 2024 founding year [LinkedIn, retrieved 2026] [The Org, retrieved 2026]. By December 2025, Flouria was speaking publicly about the women’s health gap in Dutch media, and by October 2026 the company announced that Healthy.Capital had invested, bringing total disclosed funding to €1.5 million [ABN AMRO, December 2025] [Flouria Health, October 2026].

A few operating milestones are also visible from public coverage. Flouria said it launched its consumer proposition in October 2025 and had served more than 1,000 women by October 2026, according to Femtech Insider and Startup.eu [Femtech Insider, October 2026] [Startup.eu, October 2026]. That does not yet establish retention, clinical outcomes, or repeat monetization, but it does indicate the company moved from formation into commercial deployment within roughly a year of public founding signals [Femtech Insider, October 2026] [ABN AMRO, December 2025].

Partially corroborated -- Confirmed in part by the company website and ABN AMRO, with later milestone details supported by single-source or lightly corroborated public coverage.

Under the Hood

Product and care model

MIXED Flouria is pitching a fairly specific consumer health product, not a broad wellness app. Public materials describe it as a digital women’s health clinic focused on hormonal health, with online specialist care spanning life stages such as perimenopause, fertility, PCOS, and postpartum recovery [Flouria Health, retrieved 2026]. The company’s own site also states that it offers a personalized perimenopause care trajectory that includes consultations with specialists and hormone replacement therapy prescriptions, which is a stronger and narrower claim than the broader press framing [Flouria Health, retrieved 2026].

The operating logic appears to be integrated care rather than one-off content or community. Company and press descriptions say Flouria combines consultations with testing, tracking, and personalized treatment plans, while Femtech Insider reports the company had served more than 1,000 women since launching its consumer proposition in October 2025 [Flouria Health, October 2026] [Femtech Insider, October 2026] [Startup.eu, October 2026]. That matters because the product claim rests on continuity of care across conditions and life stages, but the public record still says little about protocol depth, provider network scale, or how much of the care journey is software-mediated versus clinician-led [Flouria Health, retrieved 2026].

Technology posture

MIXED The public evidence supports a software-enabled clinic model, but not a deeply documented technology stack. Flouria’s website and coverage consistently frame the offering as digital care, and co-founder Vlatko Stojkovski is identified publicly as CTO and, according to company-linked descriptions, responsible for building the technology in-house [LinkedIn, retrieved 2026] [The Org, retrieved 2026] [Women Disrupting Tech, May 2025]. Beyond that, the company has not publicly detailed architecture, interoperability, data integrations, or any AI layer in the materials reviewed [Flouria Health, retrieved 2026].

That leaves the technology assessment fairly conservative. The strongest public read is that software is serving as the access and care-coordination layer for a clinical service, rather than standing alone as a pure SaaS product [Flouria Health, retrieved 2026] [Femtech Insider, October 2026]. If the model scales, differentiation is more likely to come from care design, clinician workflows, and patient outcomes than from a disclosed proprietary technical moat, because none has yet been substantiated in public materials [Startup.eu, October 2026] [Flouria Health, October 2026].

Partially corroborated -- Product scope is supported mainly by company materials, with partial corroboration from Femtech Insider and Startup.eu; technology specifics remain lightly documented in public sources.

Market Research

Market context

PUBLIC The market matters now because women’s hormonal health has shifted from an under-served care category to a fundable digital-health wedge, but the public evidence around Flouria still says more about timing than about addressable market size [ABN AMRO, December 2025] [Femtech Insider, October 2026].

No named third-party TAM, SAM, or SOM study appears in the supplied source set, so any sizing claim here has to be treated as analogous rather than company-specific. The public record does support the underlying demand premise: Flouria positions itself around care gaps in women’s health, and an ABN AMRO interview with co-founder Jeanine van Munster centers on the women’s healthcare gap and the financing gap facing female-founded femtech companies [ABN AMRO, December 2025]. Separately, Flouria says it launched its consumer proposition in October 2025 and had served more than 1,000 women by October 2026, which indicates at least early consumer pull in the Netherlands, though not yet enough to infer durable cohort behavior or category share [Femtech Insider, October 2026] [Startup.eu, October 2026].

The nearer way to think about market scope is through adjacent public markets rather than a precise company-defined TAM. Flouria’s own materials place it across perimenopause, fertility, PCOS, postpartum recovery, and broader hormonal care, which maps it into a blend of digital primary care, specialty women’s health, and consumer-paid telehealth rather than a single clean reimbursement bucket [Flouria Health, retrieved 2026]. That matters because the category can be large in aggregate while still fragmenting into several narrower care journeys, each with different acquisition costs, retention profiles, and regulatory requirements.

Market lens	Public evidence	Relevance to Flouria
Women’s health care gap	ABN AMRO interview discusses the healthcare gap affecting women [ABN AMRO, December 2025]	Supports category demand thesis, but not a quantified TAM
Hormonal health clinic demand	Flouria reported serving more than 1,000 women after its October 2025 consumer launch [Femtech Insider, October 2026] [Startup.eu, October 2026]	Suggests early market receptivity in the Netherlands
Femtech funding environment	ABN AMRO interview references a financing disparity for female-founded femtech companies [ABN AMRO, December 2025]	Relevant to capital formation and competitive intensity

The evidence points to real demand formation, but it is still one step removed from market sizing. Investors should read the category as plausible and expanding, while recognizing that the cited public materials do not quantify how much of that spend is reachable by a Dutch digital clinic.

Demand drivers and adjacent markets

PUBLIC The demand case rests on fragmentation in women’s care pathways and on the willingness of consumers to seek specialist support outside traditional in-person channels [Flouria Health, retrieved 2026] [Women Disrupting Tech, May 2025].

Public descriptions of the product repeatedly emphasize multi-stage care, spanning perimenopause, fertility, PCOS, postpartum recovery, testing, tracking, and personalized treatment plans [Flouria Health, retrieved 2026] [Women Disrupting Tech, May 2025]. That framing is commercially useful because it broadens the entry points into the product: a patient may first appear for fertility support, menopause symptoms, or postpartum concerns, while the platform attempts to retain her across additional hormonal-health needs. The opportunity, if that model works, is that adjacent care journeys could raise lifetime value relative to a single-condition clinic. The current public evidence does not establish whether that cross-sell actually occurs.

The main adjacent markets are easier to identify than to size from the source set. One is general telehealth, where convenience and online access are the baseline customer expectation. Another is fertility and reproductive care media and community, which matters because one co-founder, Anna Christie, is publicly tied to a women’s-health podcast, suggesting audience formation can sit alongside clinical conversion, even if no conversion data is disclosed [Apple Podcasts, retrieved 2026]. A third is menopause-focused specialist care, reinforced by Flouria’s public emphasis on perimenopause and by the named medical lead role for Lotte van Dijk as a menopause specialist [Flouria Health, retrieved 2026] [LinkedIn, retrieved 2026].

A subtle tailwind in the public record is narrative legitimacy. Flouria has been covered by category publications including Femtech Insider and Startup.eu, and interviewed in an ABN AMRO format focused on the women’s health gap [Femtech Insider, October 2026] [Startup.eu, October 2026] [ABN AMRO, December 2025]. That does not validate outcomes, but it does suggest the company is operating inside a broader cultural and investor conversation that is making women’s hormonal health easier to underwrite than it was several years ago.

Regulatory and macro forces

PUBLIC The regulatory picture is central here because Flouria is not selling generic wellness content, it is presenting itself as a digital clinic with consultations and care pathways [Flouria Health, retrieved 2026].

That distinction creates both opportunity and operating constraint. On the opportunity side, clinic-based positioning can support higher trust, potential prescription pathways, and more durable engagement than pure content or tracking apps. Flouria’s website specifically references a personalized perimenopause care trajectory including consultations with experts and prescription of HRT, which places it closer to regulated care delivery than to consumer wellness software [Flouria Health, retrieved 2026]. On the constraint side, scaling across European markets is unlikely to be a simple copy-paste motion because clinical practice, prescribing rules, and telehealth compliance can vary by country. The source set supports Flouria’s expansion ambition, but not a claim that the regulatory path has already been solved market by market [Flouria Health, October 2026] [Startup.eu, October 2026].

Macro conditions cut both ways. The positive read is that women’s health remains a visible theme for both investors and consumers, and Flouria’s October 2026 funding announcement shows there is still seed capital available for focused care models in Europe [Flouria Health, October 2026] [Inside Her, October 2026]. The limiting read is that consumer-paid healthcare businesses still have to prove efficient acquisition and repeat engagement in a tighter funding market. The public materials support category momentum, but they do not yet show whether this segment behaves more like high-frequency primary care or episodic specialty care in practice.

Partially corroborated -- Section relies on named public sources for category demand signals and company traction, but no independent third-party market sizing study is present in the supplied research.

Competition and Substitutes

MIXED Flouria is positioning itself less as a single-condition telehealth service and more as a digital clinic for hormonal health across multiple life stages, which places it against a broad set of alternatives rather than one clean peer group [Flouria Health, retrieved 2026] [Femtech Insider, October 2026].

The competitive map breaks into three layers. First are incumbents in conventional care: local gynecology practices, fertility clinics, general practitioners, and hospital outpatient services in the Netherlands, which remain the default route for diagnosis, prescribing, and specialist referrals, even if the public sources here do not name specific institutions [ABN AMRO, December 2025] [Flouria Health, retrieved 2026]. Second are digital challengers in women’s health, but the source set for this report does not name direct startup competitors, which limits any claim about exact peer overlap. Third are adjacent substitutes such as symptom-tracking apps, content-led menopause or fertility communities, and podcast-led health brands, which can acquire user attention cheaply but do not, on the evidence available, replicate Flouria’s stated combination of consultations and care pathways [Flouria Health, retrieved 2026] [Apple Podcasts, retrieved 2026].

What looks differentiated today is scope, not scale. Public materials describe Flouria as a digital clinic spanning perimenopause, fertility, postpartum issues, and related hormonal conditions, with a personalized perimenopause trajectory that includes consultations and HRT prescribing, which is broader than a narrow fertility or menopause point solution if the company can execute that operating model consistently [Flouria Health, retrieved 2026] [Startup.eu, October 2026]. The durability of that edge is still uncertain. A cross-life-stage care model can improve retention and raise customer lifetime value in theory, but in practice it is perishable unless Flouria turns early consumer demand into repeatable clinical operations, trusted brand distribution, and regulatory execution across markets [Femtech Insider, October 2026] [Inside Her, October 2026].

The main exposure is that Flouria does not appear to own a privileged channel. More than 1,000 women served since the October 2025 consumer launch is a useful early signal, but it does not yet establish category leadership, employer distribution, insurer access, or a hospital partnership network that would make customer acquisition structurally cheaper than for other women’s-health entrants [Femtech Insider, October 2026] [Startup.eu, October 2026]. Healthy.Capital adds investor credibility, though capital alone is not a moat, particularly in categories where incumbents already control prescribing relationships and where adjacent wellness products can compete for attention with lighter-weight user experiences [Flouria Health, October 2026] [Inside Her, October 2026].

Over the next 18 months, the most plausible scenario is competitive sorting by trust and care continuity rather than by feature breadth. Flouria is the most plausible winner if consumers continue to prefer a single clinic interface for multiple hormonal-health needs and if the company can translate its early cohort into repeat engagement in the Netherlands before entering additional European markets [Femtech Insider, October 2026] [Startup.eu, October 2026]. The most plausible loser if that thesis fails is Flouria itself: if users treat menopause, fertility, and postpartum as separate purchasing decisions, specialists and single-condition alternatives will likely remain advantaged because they present a simpler value proposition and may avoid the operational complexity of a full-lifecycle clinic [Flouria Health, retrieved 2026] [ABN AMRO, December 2025].

Partially corroborated -- Competitive positioning is grounded in company materials and named press coverage, but the source set does not identify direct named competitors, so peer-specific comparisons remain only partially corroborated.

Opportunity

Upside Case

PUBLIC The prize here is not a niche telehealth practice, but a scaled women’s hormonal-health platform that becomes a trusted consumer entry point for care across multiple life stages in the Netherlands first, then selected European markets, if Flouria can turn early patient adoption and a narrow initial funding base into repeatable care delivery [Femtech Insider, October 2026] [Startup.eu, October 2026] [Flouria Health, October 2026].

The headline opportunity is straightforward. Women’s hormonal health is typically treated as a set of disconnected episodes, fertility, postpartum recovery, perimenopause, and related conditions, while Flouria is presenting itself as a continuous-care clinic that spans those transitions [Flouria Health, retrieved 2026] [Femtech Insider, October 2026]. If that model works operationally, the company could become a category-defining digital clinic in Dutch women’s health: not because it has disclosed large scale yet, but because it has already moved from launch in October 2025 to serving more than 1,000 women by October 2026, while also attracting backing from Healthy.Capital and taking total disclosed funding to €1.5 million [Femtech Insider, October 2026] [Startup.eu, October 2026] [Flouria Health, October 2026]. For an early-stage care business, that combination matters. It suggests there is at least some evidence of demand, some evidence of investor confidence, and a product surface broad enough to support expansion beyond a single point solution [Femtech Insider, October 2026] [Flouria Health, retrieved 2026].

The upside paths are still few in number, which makes them easier to underwrite. They mostly depend on whether Flouria can prove that one relationship with a patient can extend across adjacent hormonal-health needs, rather than ending after a single care episode [Flouria Health, retrieved 2026] [Startup.eu, October 2026].

Scenario	What happens	Catalyst	Why it’s plausible
Dutch category leader	Flouria becomes a leading direct-to-consumer digital clinic for hormonal health in the Netherlands, with repeat engagement across perimenopause, fertility, and postpartum pathways	Continued execution after the October 2025 consumer launch, with funding used to deepen Dutch coverage [Startup.eu, October 2026] [Flouria Health, October 2026]	The company says it has already served more than 1,000 women within roughly a year of launch, which is early evidence that consumer demand exists [Femtech Insider, October 2026]
Cross-border European expansion	Flouria extends the Dutch model into additional European markets and turns localized care delivery into a regional brand	Healthy.Capital-backed expansion into other European countries, as outlined in the October 2026 funding announcement [Flouria Health, October 2026] [Inside Her, October 2026]	Management has publicly tied the new capital to growth in the Netherlands and expansion across Europe, which gives a clear stated use case for the round [Flouria Health, October 2026]
Lifecycle women’s-health platform	Flouria uses one entry point, such as perimenopause or fertility, to build a broader longitudinal care relationship and higher lifetime value per patient	Product and care-pathway expansion across life stages already described on the company’s public materials [Flouria Health, retrieved 2026]	Public positioning already spans multiple hormonal-health moments rather than a single-condition app, which is the structural prerequisite for this model [Flouria Health, retrieved 2026] [Femtech Insider, October 2026]

The compounding logic is attractive if the model proves clinically and commercially durable. A woman may first come in through one acute need, such as fertility support or perimenopause, but the company’s public positioning is built around continuity across life stages, consultations, and personalized treatment plans [Flouria Health, retrieved 2026]. That creates the possibility of a care flywheel: one trusted episode leads to a second condition area, which improves retention, supports better referral economics, and gives Flouria more chances to spread customer acquisition cost across a longer relationship. The early sign that this may be starting is simple rather than dramatic: the company did not launch as a single-condition product, and public coverage repeatedly describes a multi-stage proposition that has already served more than 1,000 women [Femtech Insider, October 2026] [Startup.eu, October 2026].

The size of the win is harder to anchor because no credible market-sizing source or directly comparable public peer is provided in the available materials. That limits precision, but not the outline of the upside. If the cross-border expansion scenario plays out and Flouria becomes one of the better-known digital women’s-health clinics in Europe, the business could plausibly grow from a national DTC clinic into a strategic platform asset for a larger healthcare, telehealth, or women’s-health buyer, or remain independent with a broader regional footprint (scenario, not a forecast) [Flouria Health, October 2026] [Inside Her, October 2026]. The factual support here is narrower than for the earlier sections of the report, so the ambition should stay conditional: the path to a large outcome exists because the company is addressing recurring, life-stage-spanning care needs with early usage and fresh capital behind it, but the public record does not yet support a numerical valuation case with the same confidence as the qualitative one [Femtech Insider, October 2026] [Flouria Health, October 2026].

Partially corroborated -- This section relies on company materials and single-source media reporting for product scope and traction, with partial corroboration for funding from multiple public sources.

Sources